Puromycin aminonucleoside
Based on 37 publication(s) in Google Scholar
Puromycin aminonucleoside (NSC 3056) is the aminonucleoside portion of the antibiotic puromycin, and used in nephrosis animal models. Puromycin aminonucleoside induces apoptosis. Puromycin aminonucleoside is a reversible inhibitor of dipeptidyl peptidase II and cytosol alanyl aminopeptidase. Puromycin aminonucleoside induces secretion of cell migrasome.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.86%
- CAS No.: 58-60-6
- Formule: C12H18N6O3
- Masse moléculaire:294.31
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Apoptosis Compound Library
HY-L003
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
Nucleotide Compound Library
HY-L044
-
Antibacterial Compound Library
HY-L049
-
Antibiotics Library
HY-L067
-
Human Metabolite Library
HY-L123
-
Metabolic Enzyme Compound Library
HY-L146
-
Protease Inhibitor Library
HY-L147
-
Cell Death Library
HY-L162
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Amino Acid Metabolism Compound Library
HY-L189
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Drug Fragment Library
HY-L904
-
MCE Kinase Hinge Binder Fragment Library
HY-L907
Publications Citing Use of MedChemExpress (MCE) Puromycin aminonucleoside
More- Nat Immunol. 2024 Jun;25(6):981-993. [Abstract]
- Drug Resist Updat. 2026 Jan:84:101319. [Abstract]
- Cancer Res. 2025 Feb 1;85(3):585-601. [Abstract]
- Nat Commun. 2024 May 7;15(1):3834. [Abstract]
- Adv Sci (Weinh). 2025 Apr 3:e2412356. [Abstract]
- Adv Sci (Weinh). 2024 Jul 9:e2406333. [Abstract]
- Adv Sci (Weinh). 2021 Jan 6;8(5):2002738. [Abstract]
- Neuro Oncol. 2024 Jul 11:noae130. [Abstract]
- Redox Biol. 2024 Nov 5:78:103419. [Abstract]
- Pharmacol Res. 2022 Aug:182:106285. [Abstract]
- Cancer Lett. 2024 Aug 6:217161. [Abstract]
- Cell Death Dis. 2026 Jan 21;17(1):98. [Abstract]
- Cell Death Dis. 2025 Nov 24;16(1):858. [Abstract]
- Cell Death Dis. 2023 Jan 26;14(1):62. [Abstract]
- J Pharm Anal. 2023 Jul;13(7):745-759. [Abstract]
- Free Radic Biol Med. 2024 Feb 1:211:47-62. [Abstract]
- Cell Prolif. 2024 Feb;57(2):e13534. [Abstract]
- COLLOID SURFACE A. 2023 Apr 13, 131458.
- J Ethnopharmacol. 2022 Jun 28:292:115171. [Abstract]
- Cancer Gene Ther. 2024 Aug;31(8):1135-1150. [Abstract]
- Int J Mol Sci. 2023 Mar 1;24(5):4756. [Abstract]
- Front Pharmacol. 2021 Mar 8:12:603453. [Abstract]
- Toxicology. 2023 Apr:488:153475. [Abstract]
- Biochim Biophys Acta Mol Basis Dis. 2025 Jan;1871(1):167533. [Abstract]
- J Inflamm Res. 2023 May 11:16:2023-2039. [Abstract]
- Ren Fail. 2024 Dec;46(2):2431150. [Abstract]
- Ren Fail. 2024 Dec;46(2):2416087. [Abstract]
- Mol Immunol. 2024 Mar:167:43-52. [Abstract]
- Vet Microbiol. 2023 Sep:284:109851. [Abstract]
- Epigenomics. 2025 Oct 30:1-8. [Abstract]
- Epigenomics. 2024;16(13):929-944. [Abstract]
- BMC Nephrol. 2023 Oct 25;24(1):309. [Abstract]
- Am J Transl Res. 2020 Jul 15;12(7):3512-3521. [Abstract]
- Phytomed Plus. 2025 Aug.
- Research Square Preprint. 2022 Jun.
- Authorea. January 20, 2021.
- Research Square Preprint. 2020 Sep.
Customer Validation & Images
-
Flow Cytometry
-
WB
Voir tous les produits spécifiques à Isoform Antibiotic
More
Activité biologique
|
DPP-2 |
Puromycin aminonucleoside (NSC 3056) (30 μg/mL) markedly increases p53 protein levels in podocytes. Puromycin aminonucleoside (NSC 3056)-induced podocyte apoptosis is p53 dependent. Puromycin aminonucleoside (NSC 3056) induces podocyte apoptosis in a time-dependent manner[2]. The IC50 values for PMAT-expressing and vector-transfected cells are 48.9 and 122.1 μM, respectively, suggesting expression of PMAT-enhanced cell sensitivity to Puromycin aminonucleoside. Puromycin aminonucleoside (NSC 3056) (250 μM) is toxic to both PMAT-expressing and vector-transfected cells. Puromycin aminonucleoside (NSC 3056) uptake in PMAT-expressing cells is fourfold higher at pH 6.6 than that at pH 7.4[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.
Puromycin aminonucleoside (PAN) can be used to induce nephrotic syndrome models[8].
Administration: 50 mg/kg • iv • single dose
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 58-60-6
-
Appearance Solid
-
Masse moléculaire 294.31
-
Formule C12H18N6O3
-
Color White to light brown
-
SMILES
N[C@H]1[C@@H](O)[C@H](N(C=N2)C3=C2C(N(C)C)=NC=N3)O[C@@H]1CO
-
Synonyms
NSC 3056
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (37)
-
Journal Impact Factor
-
Most Recent
-
Nat Immunol
An IFNγ-dependent immune-endocrine circuit lowers blood glucose to potentiate the innate antiviral immune response. [Abstract]2024 Jun;25(6):981-993. PMID: 38811816 -
Drug Resist Updat
ZBP1 antagonizes MRE11-mediated DNA end resection and confers synthetic lethality to PARP inhibition in ovarian cancer. [Abstract]2026 Jan:84:101319. PMID: 41192279 -
Cancer Res
Loss of CDKN2A Enhances the Efficacy of Immunotherapy in EGFR-Mutant Non-Small Cell Lung Cancer. [Abstract]2025 Feb 1;85(3):585-601. PMID: 39514336 -
Nat Commun
Sleep fragmentation exacerbates myocardial ischemia‒reperfusion injury by promoting copper overload in cardiomyocytes. [Abstract]2024 May 7;15(1):3834. PMID: 38714741 -
Adv Sci (Weinh)
Screening and Identification of Novel DNA Aptamer for Targeted Delivery to Injured Podocytes in Glomerular Diseases. [Abstract]2025 Apr 3:e2412356. PMID: 40178289
Puromycin aminonucleoside purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Apr 3:e2412356. [Abstract]
Analysis of the binding abilities of different aptamer pools to podocytes via flow cytometry. MPC5 cells were incubated with 250 nM of the amplified FAM-labeled products at 4℃. FAM-labeled library was used as controls. Confocal images showing f-actin in MPC5 cells after 48 h of treatment with 0.3 µg/mL adriamycin (ADR), 30 µg/mL Puromycin aminonucleoside (PAN), or 50 mm high glucose medium (HG). Untreated MPC5 cells (NC) served as the control. Actin filaments were stained with FITC-phalloidin (green), and nuclei were stained with DAPI (blue). Scale bars, 25 µm.
-
Adv Sci (Weinh)
Lactylated Apolipoprotein C-II Induces Immunotherapy Resistance by Promoting Extracellular Lipolysis. [Abstract]2024 Jul 9:e2406333. PMID: 38981044 -
Adv Sci (Weinh)
Mitochondrial Damage-Induced Innate Immune Activation in Vascular Smooth Muscle Cells Promotes Chronic Kidney Disease-Associated Plaque Vulnerability. [Abstract]2021 Jan 6;8(5):2002738. PMID: 33717842 -
Neuro Oncol
Targeting HTR2B suppresses non-functioning pituitary adenoma growth and sensitizes cabergoline treatment via inhibiting Gαq/PLC/PKCγ/STAT3 axis. [Abstract]2024 Jul 11:noae130. PMID: 38989697 -
Redox Biol
Reactivation of MAPK-SOX2 pathway confers ferroptosis sensitivity in KRASG12C inhibitor resistant tumors. [Abstract]2024 Nov 5:78:103419. PMID: 39527862 -
Pharmacol Res
Diterpenoid Vinigrol specifically activates ATF4/DDIT3-mediated PERK arm of unfolded protein response to drive non-apoptotic death of breast cancer cells. [Abstract]2022 Aug:182:106285. PMID: 35662627 -
Cancer Lett
Platelets promote primary hepatocellular carcinoma metastasis through TGF-β1-mediated cancer cell autophagy. [Abstract]2024 Aug 6:217161. PMID: 39117067 -
Cell Death Dis
Positive feedback regulation between USP8 and Hippo/YAP axis drives triple-negative breast cancer progression. [Abstract]2026 Jan 21;17(1):98. PMID: 41565619 -
Cell Death Dis
IGF2BP3 regulates EMP1 stability in an m6A-dependent manner and activates the TGF-β pathway to promote pancreatic cancer invasion. [Abstract]2025 Nov 24;16(1):858. PMID: 41285728 -
Cell Death Dis
MicroRNA miR-1275 coordinately regulates AEA/LPA signals via targeting FAAH in lipid metabolism reprogramming of gastric cancer. [Abstract]2023 Jan 26;14(1):62. PMID: 36702852 -
J Pharm Anal
Cux1+ proliferative basal cells promote epidermal hyperplasia in chronic dry skin disease identified by single-cell RNA transcriptomics. [Abstract]2023 Jul;13(7):745-759. PMID: 37577389 -
Free Radic Biol Med
TRAF2 inhibits senescence in hepatocellular carcinoma cells via regulating the ROMO1/ NAD+/SIRT3/SOD2 axis. [Abstract]2024 Feb 1:211:47-62. PMID: 38043870 -
Cell Prolif
NELFA and BCL2 induce the 2C-like state in mouse embryonic stem cells in a chemically defined medium. [Abstract]2024 Feb;57(2):e13534. PMID: 37592709 -
-
J Ethnopharmacol
Screening bioactive compounds from Danggui-shaoyao-san for treating sodium retention in nephrotic syndrome using bio-affinity ultrafiltration. [Abstract]2022 Jun 28:292:115171. PMID: 35259444 -
Cancer Gene Ther
Anti-angiogenesis and anti-immunosuppression gene therapy through targeting COUP-TFII in an in situ glioblastoma mouse model. [Abstract]2024 Aug;31(8):1135-1150. PMID: 38926596 -
Int J Mol Sci
2023 Mar 1;24(5):4756. PMID: 36902184 -
Front Pharmacol
2021 Mar 8:12:603453. PMID: 33762936 -
Toxicology
Inhibitory effects of flavonoids on glucose transporter 1 (GLUT1): From library screening to biological evaluation to structure-activity relationship. [Abstract]2023 Apr:488:153475. PMID: 36870413 -
Biochim Biophys Acta Mol Basis Dis
Trim21 modulates endoplasmic reticulum-associated degradation and sensitizes cancer cells to ER stress-induced apoptosis by inhibiting VCP/Npl4/UFD1 assembly. [Abstract]2025 Jan;1871(1):167533. PMID: 39368714 -
J Inflamm Res
Mesenchymal Stem Cells Ameliorate DSS-Induced Experimental Colitis by Modulating the Gut Microbiota and MUC-1 Pathway. [Abstract]2023 May 11:16:2023-2039. PMID: 37197438 -
Ren Fail
TRPC6 knockdown-mediated ERK1/2 inactivation alleviates podocyte injury in minimal change disease via upregulating Lon peptidase 1. [Abstract]2024 Dec;46(2):2431150. PMID: 39566913 -
Ren Fail
Circulating RAC1 contributed to steroid-sensitive nephrotic syndrome: Mendelian randomization, single-cell RNA-sequencing, proteomic, and experimental evidence. [Abstract]2024 Dec;46(2):2416087. PMID: 39422242 -
Mol Immunol
Empagliflozin attenuates inflammation levels in autoimmune myocarditis through the STAT3 pathway and macrophage phenotype transformation. [Abstract]2024 Mar:167:43-52. PMID: 38354482 -
Vet Microbiol
Newcastle disease virus nucleocapsid protein mediates the degradation of 14-3-3ε to antagonize the interferon response and promote viral replication. [Abstract]2023 Sep:284:109851. PMID: 37598526 -
Epigenomics
Defect of MLH1 expression sensitized esophageal squamous cell carcinoma cells to Polθ inhibitor. [Abstract]2025 Oct 30:1-8. PMID: 41163511 -
Epigenomics
Epigenetic silencing of KCTD8 promotes hepatocellular carcinoma growth by activating PI3K/AKT signaling. [Abstract]2024;16(13):929-944. PMID: 39023358 -
BMC Nephrol
Characteristics of sodium and water retention in rats with nephrotic syndrome induced by puromycin aminonucleoside. [Abstract]2023 Oct 25;24(1):309. PMID: 37880610 -
Am J Transl Res
Astragaloside IV alleviates puromycin aminonucleoside-induced podocyte cytoskeleton injury through the Wnt/PCP pathway. [Abstract]2020 Jul 15;12(7):3512-3521. PMID: 32774716
Puromycin aminonucleoside purchased from MedChemExpress. Usage Cited in: Am J Transl Res. 2020 Jul 15;12(7):3512-3521. [Abstract]
Expression of downstream proteins of the PCP pathway, such as ROCK1 and Rac1, is decreased in the Puromycin aminonucleoside (PAN) group and significantly enhanced by AS-IV treatment.
-
-
-
-
Solvant et solubilité
H2O : 40 mg/mL (135.91 mM; ultrasonic and warming and heat to 50°C)
DMSO : 25 mg/mL (84.94 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (7.07 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (7.07 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 12.5 mg/mL (42.47 mM); Clear solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Protocole
Cells are seeded in MEM with 10% FBS on 96-well plates at a density of 5,000 cells/well. After appr 48-h incubation (appr 40-50% confluence), cells are changed to fresh growth medium containing Puromycin aminonucleoside (NSC 3056) at various concentrations. For the protection experiment, cells are incubated in medium containing 250 μM Puromycin aminonucleoside (NSC 3056) with or without the PMAT inhibitor decynium-22 (2 μM). After a total of 72-h incubation in a 95% O2 incubator at 37°C, cells are washed and the plates. The IC50 values are determined by fitting the cell growth data to the following model using nonlinear regression (WinNonLin version 3.2): S=Smax − [Smax − S0] × [Cγ/(Cγ + IC50γ)], where S is the cell survival expressed as percentage of the optical density to untreated control cells, Smax is the maximal cell survival, S0 is the lowest residual cell survival at the high drug concentration, C is Puromycin aminonucleoside concentration, γ is the Hill coefficient, and IC50 is the Puromycin aminonucleoside concentration leading to half-maximal cell survival. Five to six determinations are carried out within each experiment, and four independent experiments are performed.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Male F344 rats at 11 weeks of age are purchased from JaPuromycin aminonucleoside SLC. Normal rats and a Puromycin aminonucleoside nephrosis model are used in the present study. Puromycin aminonucleoside (NSC 3056) nephrosis is induced in rats by a single intravenous injection of Puromycin aminonucleoside at a dose of 8 mg/100 g body weight in saline. Control animals receive an identical volume of saline. Nephrotic rats (n=6 per group) are studied at Days 4 and 7 after the Puromycin aminonucleoside injection.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureté et documentation
-
Fiche technique (287 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Lacalle RA, et al. Cloning of the complete biosynthetic gene cluster for an aminonucleoside antibiotic, puromycin, and its regulated expression in heterologous hosts. EMBO J. 1992 Feb;11(2):785-92. [Content Brief]
[2]. Wada T, et al. Prevents podocyte apoptosis induced by puromycin aminonucleoside: role of p53 and Bcl-2-related family proteins. J Am Soc Nephrol. 2005 Sep;16(9):2615-25. [Content Brief]
[3]. Gong W, et al. Estrogen-related receptor-α mediates puromycin aminonucleoside-induced mesangial cell apoptosis and inflammatory injury. Am J Physiol Renal Physiol. 2019 May 1;316(5):F906-F913. [Content Brief]
[4]. Ying Liu, et al. Podocyte-Released Migrasomes in Urine Serve as an Indicator for Early Podocyte Injury. Kidney Dis (Basel). 2020 Nov;6(6):422-433. [Content Brief]
[5]. Xia L, et al. Podocyte-specific expression of organic cation transporter PMAT: implication in puromycin aminonucleosidenephrotoxicity. Am J Physiol Renal Physiol. 2009 Jun;296(6):F1307-13. [Content Brief]
[6]. Kawakami H, et al. Dynamics of absolute amount of nephrin in a single podocyte in puromycin aminonucleoside nephrosis rats calculated by quantitative glomerular proteomics approach with selected reaction monitoring mode. Nephrol Dial Transplant. 2012 Apr; [Content Brief]
[7]. Nosaka K, et al. An adenosine deaminase inhibitor prevents puromycin aminonucleoside nephrotoxicity. Free Radic Biol Med 1997 ;22 (4): 597-605. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / H2O | 1 mM | 3.3978 mL | 16.9889 mL | 33.9778 mL | 84.9444 mL |
| 5 mM | 0.6796 mL | 3.3978 mL | 6.7956 mL | 16.9889 mL | |
| 10 mM | 0.3398 mL | 1.6989 mL | 3.3978 mL | 8.4944 mL | |
| 15 mM | 0.2265 mL | 1.1326 mL | 2.2652 mL | 5.6630 mL | |
| 20 mM | 0.1699 mL | 0.8494 mL | 1.6989 mL | 4.2472 mL | |
| 25 mM | 0.1359 mL | 0.6796 mL | 1.3591 mL | 3.3978 mL | |
| 30 mM | 0.1133 mL | 0.5663 mL | 1.1326 mL | 2.8315 mL | |
| 40 mM | 0.0849 mL | 0.4247 mL | 0.8494 mL | 2.1236 mL | |
| 50 mM | 0.0680 mL | 0.3398 mL | 0.6796 mL | 1.6989 mL | |
| 60 mM | 0.0566 mL | 0.2831 mL | 0.5663 mL | 1.4157 mL | |
| 80 mM | 0.0425 mL | 0.2124 mL | 0.4247 mL | 1.0618 mL | |
| H2O | 100 mM | 0.0340 mL | 0.1699 mL | 0.3398 mL | 0.8494 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Puromycin aminonucleoside Related Classifications
HY-15695 Related Classifications
Powered by Bioz